CALS and ACB Scales are Associated with Physical and Cognitive Impairment and Predict Mortality in Nursing Home Residents

Luca Soraci; Ersilia Paparazzo; Mirella Aurora Aceto; Francesco Bruno; Teresa Serra Cassano; Davide Lagrotteria; Salvatore Claudio Cosimo; Pierluigi Mercatante; Francesco Morelli; Maria Princiotto; Andrea Corsonello; Giuseppe Passarino; Alberto Montesanto

doi:10.1007/s40801-025-00509-7

journal article Open Access Jul 26, 2025

CALS and ACB Scales are Associated with Physical and Cognitive Impairment and Predict Mortality in Nursing Home Residents

Luca Soraci

Ersilia Paparazzo Mirella Aurora Aceto Francesco Bruno

Teresa Serra Cassano Davide Lagrotteria Salvatore Claudio Cosimo Pierluigi Mercatante Francesco Morelli Maria Princiotto Andrea Corsonello Giuseppe Passarino

Alberto Montesanto

Drugs - Real World Outcomes Vol. 12 No. 3 pp. 437-446 · Springer Science and Business Media LLC

View at Publisher Save 10.1007/s40801-025-00509-7

Topics

No keywords indexed for this article. Browse by subject →

References

44

[1]

Evans T, Binns H, Mandal AK, et al. The impact of anticholinergic burden on clinical outcomes in older hospitalised surgical patients. Br J Hosp Med. 2024;85(1):1–9. https://doi.org/10.12968/hmed.2023.0034. 10.12968/hmed.2023.0034

[2]

Nishtala PS, Allore H, Han L, et al. Impact of anticholinergic burden on cognitive performance: a cohort study of community-dwelling older adults. J Am Med Dir Assoc. 2020;21(9):1357-8.e1353. https://doi.org/10.1016/j.jamda.2020.03.027. 10.1016/j.jamda.2020.03.027

[3]

Huh Y, Kim YJ, Choi JY, et al. Comparison of anticholinergic burden with chronic polypharmacy on functional decline and mortality in Korean older people: a retrospective nationwide cohort study. BMC Geriatr. 2024;24(1): 90. https://doi.org/10.1186/s12877-024-04692-0. 10.1186/s12877-024-04692-0

[4]

D’Alia S, Guarasci F, Bartucci L, et al. Hand grip strength may affect the association between anticholinergic burden and mortality among older patients discharged from hospital. Drugs Aging. 2020;37(6):447–55. https://doi.org/10.1007/s40266-020-00766-x. 10.1007/s40266-020-00766-x

[5]

Corsonello A, Soraci L, Corica F, et al. The interplay between anticholinergic burden and anemia in relation to 1-year mortality among older patients discharged from acute care hospitals. J Clin Med. 2021;10(20):4650. https://doi.org/10.3390/jcm10204650. 10.3390/jcm10204650

[6]

Brombo G, Bianchi L, Maietti E, et al. Association of anticholinergic drug burden with cognitive and functional decline over time in older inpatients: results from the CRIME project. Drugs Aging. 2018;35(10):917–24. https://doi.org/10.1007/s40266-018-0584-9. 10.1007/s40266-018-0584-9

[7]

Lattanzio F, Corica F, Schepisi R, et al. Anticholinergic burden and 1-year mortality among older patients discharged from acute care hospital. Geriatr Gerontol Int. 2018;18(5):705–13. https://doi.org/10.1111/ggi.13234. 10.1111/ggi.13234

[8]

Norling AM, Bennett A, Crowe M, et al. Longitudinal associations of anticholinergic medications on cognition and possible mitigating role of physical activity. J Am Geriatr Soc. 2023;71(6):1937–43. https://doi.org/10.1111/jgs.18279. 10.1111/jgs.18279

[9]

Ramos H, Moreno L, Perez-Tur J, et al. CRIDECO anticholinergic load scale: an updated anticholinergic burden scale. Comparison with the ACB scale in Spanish individuals with subjective memory complaints. J Pers Med. 2022;12(2):207. https://doi.org/10.3390/jpm12020207. 10.3390/jpm12020207

[10]

Malkiewicz JJ, Kasprzyk AG, Waksmundzki D, et al. Risk factors for dementia in Parkinson’s disease: the overuse of anticholinergic drugs. Neurol Neurochir Pol. 2023;57(5):405–13. https://doi.org/10.5603/PJNNS.a2023.0041. 10.5603/pjnns.a2023.0041

[11]

Yoshimatsu Y, Kragholm K, Clemmensen SZ, et al. The predictive value of anticholinergic drug exposure and the outcome of pneumonia: a Danish database study. Age Ageing. 2024;53(2): afae012. https://doi.org/10.1093/ageing/afae012. 10.1093/ageing/afae012

[12]

Novella A, Azab M, Pasina L. Comparison of anticholinergic burden scales and their association with cognitive and functional impairment in older adults: a cross-sectional study using the REPOSI database. Drugs Aging. 2025;42(6):559–72. https://doi.org/10.1007/s40266-025-01204-6. 10.1007/s40266-025-01204-6

[13]

Cherubini A, Corsonello A, Lattanzio F. Polypharmacy in nursing home residents: what is the way forward? J Am Med Dir Assoc. 2016;17(1):4–6. https://doi.org/10.1016/j.jamda.2015.07.008. 10.1016/j.jamda.2015.07.008

[14]

Díez R, Cadenas R, Susperregui J, et al. Potentially inappropriate medication and polypharmacy in nursing home residents: a cross-sectional study. J Clin Med. 2022;11(13):3808. https://doi.org/10.3390/jcm11133808. 10.3390/jcm11133808

[15]

Dufournet M, Dauphinot V, Moutet C, et al. Impact of cognitive, functional, behavioral disorders, and caregiver burden on the risk of nursing home placement. J Am Med Dir Assoc. 2019;20(10):1254–62. https://doi.org/10.1016/j.jamda.2019.03.027. 10.1016/j.jamda.2019.03.027

[16]

Moreno-Martin P, Jerez-Roig J, Rierola-Fochs S, et al. Incidence and predictive factors of functional decline in older people living in nursing homes: a systematic review. J Am Med Dir Assoc. 2022;23(11):1815-25.e1819. https://doi.org/10.1016/j.jamda.2022.05.001. 10.1016/j.jamda.2022.05.001

[17]

Paparazzo E, Geracitano S, Lagani V, et al. Clinical and prognostic implications of estimating glomerular filtration rate by three different creatinine-based equations in older nursing home residents. Front Med. 2022;9: 870835. https://doi.org/10.3389/fmed.2022.870835. 10.3389/fmed.2022.870835

[18]

Kolanowski A, Fick DM, Campbell J, et al. A preliminary study of anticholinergic burden and relationship to a quality of life indicator, engagement in activities, in nursing home residents with dementia. J Am Med Dir Assoc. 2009;10(4):252–7. https://doi.org/10.1016/j.jamda.2008.11.005. 10.1016/j.jamda.2008.11.005

[19]

Use of anticholinergics and the risk of cognitive impairment in an African American population

N.L. Campbell, M.A. Boustani, K.A. Lane et al.

Neurology 2010 10.1212/wnl.0b013e3181e7f2ab

[20]

Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011;59(8):1477–83. https://doi.org/10.1111/j.1532-5415.2011.03491.x. 10.1111/j.1532-5415.2011.03491.x

[21]

Carnahan RM, Lund BC, Perry PJ, et al. The anticholinergic drug scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46(12):1481–6. https://doi.org/10.1177/0091270006292126. 10.1177/0091270006292126

[22]

Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review

Mohammed Saji Salahudeen, Stephen B Duffull, Prasad S Nishtala

BMC Geriatrics 2015 10.1186/s12877-015-0029-9

[23]

Stevenson DG, Dusetzina SB, O’Malley AJ, et al. High-risk medication use by nursing home residents before and after hospitalization. Med Care. 2014;52(10):884–90. https://doi.org/10.1097/mlr.0000000000000214. 10.1097/mlr.0000000000000214

[24]

Progress in Development of the Index of ADL

S. Katz, T. D. Downs, H. R. Cash et al.

The Gerontologist 1970 10.1093/geront/10.1_part_1.20

[25]

“Mini-mental state”

Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh

Journal of Psychiatric Research 1975 10.1016/0022-3956(75)90026-6

[26]

Braekhus A, Laake K, Engedal K. A low, “normal” score on the mini-mental state examination predicts development of dementia after three years. J Am Geriatr Soc. 1995;43(6):656–61. https://doi.org/10.1111/j.1532-5415.1995.tb07201.x. 10.1111/j.1532-5415.1995.tb07201.x

[27]

Vellas B, Guigoz Y, Garry PJ, et al. The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients. Nutrition. 1999;15(2):116–22. https://doi.org/10.1016/s0899-9007(98)00171-3. 10.1016/s0899-9007(98)00171-3

[28]

Kaiser MJ, Bauer JM, Ramsch C, et al. Validation of the mini nutritional assessment short-form (MNA-SF): a practical tool for identification of nutritional status. J Nutr Health Aging. 2009;13(9):782–8. https://doi.org/10.1007/s12603-009-0214-7. 10.1007/s12603-009-0214-7

[29]

Conwell Y, Forbes NT, Cox C, et al. Validation of a measure of physical illness burden at autopsy: the cumulative illness rating scale. J Am Geriatr Soc. 1993;41(1):38–41. https://doi.org/10.1111/j.1532-5415.1993.tb05945.x. 10.1111/j.1532-5415.1993.tb05945.x

[30]

Tsamardinos I, Rakhshani A, Lagani V. Performance-estimation properties of cross-validation-based protocols with simultaneous hyper-parameter optimization. 2015;24(05):1540023. https://doi.org/10.1142/s0218213015400230. 10.1142/s0218213015400230

[31]

Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–7. https://doi.org/10.1001/jamainternmed.2014.7663. 10.1001/jamainternmed.2014.7663

[32]

Grossi CM, Richardson K, Fox C, et al. Anticholinergic and benzodiazepine medication use and risk of incident dementia: a UK cohort study. BMC Geriatr. 2019;19(1):276. https://doi.org/10.1186/s12877-019-1280-2. 10.1186/s12877-019-1280-2

[33]

Graves-Morris K, Stewart C, Soiza RL, et al. The prognostic value of anticholinergic burden measures in relation to mortality in older individuals: a systematic review and meta-analysis. Front Pharmacol. 2020;11:570. https://doi.org/10.3389/fphar.2020.00570. 10.3389/fphar.2020.00570

[34]

Staff Awareness of Anti-Cholinergic Burden (ACB) - A Qualitative Cross-Sectional Study in a Tertiary Care Hospital

Kamalaveni Soundararajan, Pooja Balchandra

Cureus 2021 10.7759/cureus.14141

[35]

Ramos H, Moreno L, Gil M, et al. Pharmacists’ knowledge of factors associated with dementia: the A-to-Z dementia knowledge list. Int J Environ Res Public Health. 2021;18(19): 9934. 10.3390/ijerph18199934

[36]

Grill P, Marwick C, De Souza N, et al. The burden of psychotropic and anticholinergic medicines use in care homes: population-based analysis in 147 care homes. Age Ageing. 2020;50(1):183–9. https://doi.org/10.1093/ageing/afaa122. 10.1093/ageing/afaa122

[37]

Naples JG, Marcum ZA, Perera S, et al. Concordance between anticholinergic burden scales. J Am Geriatr Soc. 2015;63(10):2120–4. https://doi.org/10.1111/jgs.13647. 10.1111/jgs.13647

[38]

Landi F, Dell’Aquila G, Collamati A, et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. J Am Med Dir Assoc. 2014;15(11):825–9. https://doi.org/10.1016/j.jamda.2014.08.002. 10.1016/j.jamda.2014.08.002

[39]

Vetrano DL, La Carpia D, Grande G, et al. Anticholinergic medication burden and 5-year risk of hospitalization and death in nursing home elderly residents with coronary artery disease. J Am Med Dir Assoc. 2016;17(11):1056–9. https://doi.org/10.1016/j.jamda.2016.07.012. 10.1016/j.jamda.2016.07.012

[40]

Lahiry S, Chatterjee M, Chatterjee S. Impact of oral anticholinergic on insulin response to oral glucose load in patients with impaired glucose tolerance. Indian J Pharmacol. 2021;53(4):294–7. https://doi.org/10.4103/ijp.IJP_792_19. 10.4103/ijp.ijp_792_19

[41]

Myint PK, Fox C, Kwok CS, et al. Total anticholinergic burden and risk of mortality and cardiovascular disease over 10 years in 21,636 middle-aged and older men and women of EPIC-Norfolk prospective population study. Age Ageing. 2015;44(2):219–25. https://doi.org/10.1093/ageing/afu185. 10.1093/ageing/afu185

[42]

Koekkoek PS, Kappelle LJ, van den Berg E, et al. Cognitive function in patients with diabetes mellitus: guidance for daily care. Lancet Neurol. 2015;14(3):329–40. https://doi.org/10.1016/s1474-4422(14)70249-2. 10.1016/s1474-4422(14)70249-2

[43]

Margolis SA, Zughaft Sears M, Daiello LA, et al. Anticholinergic/sedative drug burden predicts worse memory acquisition in older racially/ethnically diverse patients with type 2 diabetes mellitus. Int J Geriatr Psychiatry. 2019;34(10):1545–54. https://doi.org/10.1002/gps.5173. 10.1002/gps.5173

[44]

Nishtala PS, Hilmer SN, McLachlan AJ, et al. Impact of residential medication management reviews on drug burden index in aged-care homes: a retrospective analysis. Drugs Aging. 2009;26(8):677–86. https://doi.org/10.2165/11316440-000000000-00000. 10.2165/11316440-000000000-00000

Metrics

2

Citations

44

References

Details

Published: Jul 26, 2025
Vol/Issue: 12(3)
Pages: 437-446
License: View

Authors

Salvatore Claudio Cosimo

Department of Biology, Ecology and Earth Sciences, University of Calabria, 87036 Rende, CS, Italy

A

Alberto Montesanto

Department of Biology, Ecology and Earth Sciences, University of Calabria, 87036 Rende, CS, Italy

Funding

Italian Ministry of Health Award: Next Generation EU [DM 1557 11.10.2022]

Cite This Article

Luca Soraci, Ersilia Paparazzo, Mirella Aurora Aceto, et al. (2025). CALS and ACB Scales are Associated with Physical and Cognitive Impairment and Predict Mortality in Nursing Home Residents. Drugs - Real World Outcomes, 12(3), 437-446. https://doi.org/10.1007/s40801-025-00509-7

CALS and ACB Scales are Associated with Physical and Cognitive Impairment and Predict Mortality in Nursing Home Residents

You May Also Like